Having leapt the cardiovascular (CV)-risk hurdle set by the FDA for Contrave (naltrexone/bupropion) with early results from the Phase III trial known as the Light Study, Orexigen Therapeutics Inc. can start to resubmit its new drug application (NDA) for the obesity drug, which could be approved in the U.S. by next summer.